

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.- 2. (Cancelled)

3. (Previously Presented) A method of treating and/or preventing a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering an antiseecretory protein inducing food made from malted cereals in the manufacture of a food or medical food.

4. (Previously Presented) A method of treating and/or preventing a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering a food or medical food comprising an egg yolk with at least 1000 FIL units/ml, of antiseecretory protein.

5. (Previously Presented) A method of treating and/or preventing a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering a medicament comprising an egg yolk with at least 1000 FIL units/ml, of antiseecretory protein.

6. - 15. (Cancelled)

16. (Previously Presented) A method of inducing the formation of the antisecretory protein according to claim 23, comprising administering a food and/or drinking solution made from malted cereal.

17. - 19. (Cancelled)

20. (Currently Amended) A method of propagating, inducing, reducing and/or maintaining the genesis of an isolated stem cell and/or stem cell progeny from any germinal layer *in vitro*, comprising treating the isolated cell with an antisecretory protein or an oligo- or polypeptide or derivatives thereof comprising an amino acid sequence of Formula I:

X1-V-C-X2-X3-K-X4-R-X5 (Formula I; SEQ ID NOS: 3-6)

wherein

X1 is I, amino acids nos. 1-35 of ~~SEQ ID NO: 2~~SEQ ID NO. 1, or is absent

X2 is H, R or K

X3 is S or L

X4 is T or A

X5 is amino acids nos. 43-46 (SEQ ID NO: 3), 43-51 (SEQ ID NO: 4), 43-80 (SEQ ID NO: 5) or 43-163 (SEQ ID NO: 6) of SEQ ID NO:1, or is absent; or a pharmaceutically acceptable salt thereof.

21. (Currently Amended) The method according to claim 20, wherein Formula I has a sequence chosen from one of:

- a) amino acids numbers 35-42 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- b) amino acids numbers 35-46 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- c) amino acids numbers 36-51 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- d) amino acids numbers 36-80 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- e) amino acids numbers 1-80 of ~~SEQ ID NO:2~~SEQ ID NO. 1, or
- f) amino acids numbers 1-163 of ~~SEQ ID NO:2~~SEQ ID NO. 1

or a pharmaceutically acceptable salt thereof.

22. (Previously Presented) The method according to claim 20, wherein said isolated cell is chosen from the group comprising epithelial cells, fibroblasts, osteogenic cells, macrophages and microglial cells, vascular cells, bone cells, chondrocytes, myocardial cells, blood cells, neurons, oligodendrocytes, astroglial cells, progenitor cells, stem cells and/or cells derived from progenitor cells or stem cells.

23. (Currently Amended) A method of treatment and/or prevention of a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering to a patient in need thereof an effective amount of an antisecretory protein, or an oligo- or polypeptide or derivatives thereof comprising an amino acid sequence of Formula I:

X1-V-C-X2-X3-K-X4-R-X5 (Formula I; SEQ ID NOS:3-6)

wherein

X1 is I, amino acids nos. 1-35 of ~~SEQ ID NO:2~~SEQ ID NO. 1, or is absent

X2 is H, R or K

X3 is S or L

X4 is T or A

X5 is amino acids nos. 43-46 (SEQ ID NO: 3), 43-51 (SEQ ID NO: 4), 43-80 (SEQ ID NO: 5) or 43-163 (SEQ ID NO: 6) of SEQ ID NO:1, or is absent; or a pharmaceutically acceptable salt thereof.

24. (Currently Amended) The method according to claim 23, wherein Formula I has a sequence chosen from one of:

- a) amino acids nos. 35-42 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- b) amino acids nos. 35-46 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- c) amino acids nos. 36-51 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- d) amino acids nos. 36-80 of ~~SEQ ID NO:2~~SEQ ID NO. 1,
- e) amino acids nos. 1-80 of ~~SEQ ID NO:2~~SEQ ID NO. 1, or
- f) amino acids numbers 1-163 of ~~SEQ ID NO:2~~SEQ ID NO. 1

or a pharmaceutically acceptable salt thereof.

25. (Previously Presented) The method according to claim 23, wherein the condition is characterized by displaying a pathological degeneration of, loss of ability and/or loss of control of regeneration of and/or loss of control of regeneration of a differentiated cell and/or tissue, an embryonic stem cell, an adult stem cell, a progenitor cell and/or a cell derived from a stem cell or progenitor cell.

26. (Previously Presented) The method according to claim 23, wherein the condition is associated with or characterized by a pathological loss and/or gain of cells in the peripheral, autonomic or central nervous system.

27. (Previously Presented) The method according to claim 23, wherein the condition is associated with or characterized by a pathological loss and/or gain of neural stem cells or neural progenitor cells.

28. (Previously Presented) The method according to claim 23, wherein the condition is associated with or characterized by a pathological loss and/or gain of oligodendroglial, astroglial, Schwann cells, and/or neuronal cells and/or cell populations.

29. (Previously Presented) The method according to claim 28, wherein the condition is associated with or characterized by a pathological loss and/or gain of non-cholinergic neuronal cells, cholinergic neuronal cells and/or glial cells, and/or cell populations.

30. (Previously Presented) The method according to claim 23, wherein the condition is caused by damage to the central nervous system or a defect in the central nervous system.

31. (Previously Presented) The method according to claim 23, wherein the condition is caused by a traumatic, auto-immune or degenerative disorder.

32. (Previously Presented) The method according to claim 23, wherein the condition is caused by axonal damage caused by concussion, contusion, axonal damage caused by head trauma, axonal damage caused by small vessel disease in the CNS and/or damage to the spinal cord after disease and/or trauma.

33. (Previously Presented) The method according to claim 23, wherein said condition is characterised by memory loss.

34. (Previously Presented) The method according to claim 23, wherein the condition is multiple sclerosis, asphyxia, hypoxic injury, ischemic injury, traumatic injury, Parkinson's disease, Alzheimer's disease, stroke, or demyelinating disorder.

35. (Previously Presented) The method according to claim 23, wherein the antisecretory protein or the oligo- or polypeptide or derivatives thereof is formulated into a medicament for intravenous infusion, intramuscular injection and/or subcutaneous injection.

36. (Previously Presented) The method according to claim 21, wherein the antisecretory protein or the oligo- or polypeptide or derivatives thereof is formulated into a medicament so that the active substance will pass into the ventricles and /or other cavities in and/or at a patient's brain when it is administered to said patient.

37. (Previously Presented) The method according to claim 21, wherein the antisecretory protein or the oligo- or polypeptide or derivatives thereof is formulated into a medicament so that the active substance will pass into the cerebrospinal fluid of a patient when it is administered to said patient.

38. (Previously Presented) A method of propagating, inducing, reducing and/or maintaining the genesis of an isolated stem cell and/or stem cell progeny from any germinal layer from a patient, characterized by:

a) administering an effective amount of an antisecretory protein or an oligo- or polypeptide or derivatives thereof comprising the amino acid sequence of Formula I as defined in claim 23 to said patient prior to isolating said cell;

b) propagating said isolated cell *in vitro*;

followed by

c) transplanting said propagated cells into the same or another patient in need thereof.

39. (Previously Presented) A method of propagating, inducing, reducing and/or maintaining the genesis of an isolated stem cell and/or stem cell progeny from any germinal layer from a patient, characterized by:

a) isolating said cell and/or stem cell progeny from the patient;

b) administering an effective amount of an antisecretory protein or an oligo- or polypeptide or derivatives thereof comprising the amino acid sequence of Formula I as defined in claim 23 to said isolated cell *in vitro* and propagating said cells; followed by

c) transplanting said propagated cells back into the same or another patient in need thereof.

40. (Previously Presented) The method according to claim 38, wherein said isolated cell is selected from the group consisting of fibroblasts, macrophages, vascular cells, bone cells, chondrocytes, myocardial cells, blood cells, neurons, oligodendrocytes, astroglial cells, Schwann cells, progenitor cells, stem cells and/or cells derived from progenitor cells or stem cells.

41. (Previously Presented) The method of claim 23, wherein the condition is associated with insufficient formation of antiseecretory factors.

42. (Previously Presented) The method of claim 23, wherein the condition is associated with insufficient function of the AF receptors and antiseecretory factor binding tissue constituents.